ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 10 of 59
УЖМБС 2020, 5(5): 82–89
Clinical Medicine

Influence of Antihypertensive Therapy depending on the Classes of Drugs on the Level of New Biomarkers of Inflammation GDF-15, P-Selectin and Galectin-3 in Patients with Hypertension in Combination with Type 2 Diabetes

Bilchenko A. O.

The purpose of the study was to assess the impact of antihypertensive therapy depending on the classes of drugs on the level of new biomarkers of inflammation: GDF-15, P-selectin and Galectin-3 in blood plasma in patients with hypertension in combination with type 2 diabetes. Material and methods. The study included 121 patients, including 59 women and 62 men aged 40 to 87 years (mean age 64.7±10.6 years). We determined the levels of new biomarkers of inflammation (GDF-15, P-selectin, Galectin-3), and a reference marker of systemic inflammation (high-sensitive CRP (hs-CRP) using standard kits in patients who participated in the study. We also evaluated the effect of different classes of antihypertensive drugs at the level of new biomarkers. Results and discussion. In the group of patients with unattainable target blood pressure, the level of GDF-15 was significantly higher compared with the group of patients whose target level of "office" blood pressure was achieved at the time of inclusion in the study (3286.10±1523.02 and 2326.60±1581.70 ng / ml, p <0.05, respectively). At the same time, plasma levels of P-selectin and Galectin-3 in patients did not differ significantly. After 12 months of hypertension treatment, depending on the achievement of blood pressure control showed that in the group of patients who managed to achieve the target "office" blood pressure, the level of GDF-15 was significantly lower than in the group of patients who did not reach the target level of "office" blood pressure after 12 months of treatment (3129.67±1134.87 and 2543.12±976.54 ng / ml, p <0.05, respectively). Changes of P-selectin, Galectin-3 and hs-CRP were insignificant after 12 months of treatment of hypertension. Baseline plasma levels GDF-15, P-selectin, Galectin-3 and hs-CRP in patients who received or did not receive RAAS blockers had no significant difference. There was a significantly lower baseline level of GDF-15 in the group of patients receiving CCB (2343.42±1280.70 and 3248.29±1178.56 pg / ml, p = 0.05, respectively). Baseline plasma levels of P-selectin, Galectin-3 and hs-CRP in patients who took or did not take CCB did not have a significant difference. According to the meta-analysis of the chances of taking the drugs had a significant effect on the level of GDF-15, while some groups of drugs did not show a significant additional risk of affecting the level of GDF-15 in patients. Conclusion. The dependence of the GDF-15 level on the achievement of the "target" level of blood pressure can be explained by the positive impact on hemodynamics and structural changes in the cardiovascular system due to better control of blood pressure per se. Antihypertensive drugs affect different pathogenetic mechanisms of inflammation in different ways. According to the analysis of the chances, CCB had the greatest impact on reducing the level of GDF-15. None of the classes of antihypertensive drugs had a significant effect on the level of Galectin-3, and there was a tendency to lower levels of hs-CRP in patients taking blockers of RAS and CCB. The level of P-selectin decreased in patients taking β-blockers due to concomitant use of antiplatelets and anticoagulants

Keywords: systemic inflammation, cardiovascular risk, therapy of arterial hypertension, "residual inflammatory risk"

Full text: PDF (Ukr) 314K

  1. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. Oxford University Press. 2016; 37: 2315-2381. PMid:27222591 PMCid:PMC4986030
  2. Raggi P, Genest J, Giles JT, Rayner KJ, Dwivedi G, Beanlands RS, et al. Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions. Atherosclerosis. 2018 Sep; 276: 98-108. PMid:30055326
  3. Abdolmaleki F, Gheibi Hayat SM, Bianconi V, Johnston TP, Sahebkar A. Atherosclerosis and immunity: A perspective. Trends in Cardiovascular Medicine. 2019 Aug; 29(6): 363-371. PMid:30292470
  4. Ridker PM. Anticytokine Agents. Circulation Research. 2019 Feb; 124(3): 437-450. PMid:30702995 PMCid:PMC6386195
  5. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women. New England Journal of Medicine. 2000 Mar 23; 342(12): 836-843. PMid:10733371
  6. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine. 2017 Sep 21; 377(12): 1119-1131. PMid:28845751
  7. Herrero-Fernandez, Gomez-Bris, Somovilla-Crespo, Gonzalez-Granado. Immunobiology of Atherosclerosis: A Complex Net of Interactions. International Journal of Molecular Sciences. 2019 Oct 24; 20(21): 5293. PMid:31653058 PMCid:PMC6862594
  8. Buda V, Andor M, Cristescu C, Voicu M, Cochera F, Tuduce P, et al. The effect of candesartan on pentraxin-3 plasma levels as marker of endothelial dysfunction in patients with essential arterial hypertension. Irish Journal of Medical Science. 2017 Aug 21; 186(3): 621629. PMid:28220370
  9. Wu Y, Potempa LA, el Kebir D, Filep JG. C-reactive protein and inflammation: conformational changes affect function. Biological Chemistry. 2015 Nov 1; 396(11): 1181-1197. PMid:26040008
  10. Schnabel RB, Yin X, Larson MG, Yamamoto JF, Fontes JD, Kathiresan S, et al. Multiple Inflammatory Biomarkers in Relation to Cardiovascular Events and Mortality in the Community. Arteriosclerosis, Thrombosis, and Vascular Biology. 2013 Jul; 33(7): 1728-1733. PMid:23640499 PMCid:PMC3753537
  11. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for themanagement of arterial hypertension. European Heart Journal. Oxford University Press. 2018; 39: 3021-3104. PMid:30990869
  12. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020 Jan 20; 43(Suppl 1): S14-31. PMid:31862745
  13. Vermeulen B, Schutte AE, Gafane-Matemane LF, Kruger R. Growth differentiating factor-15 and its association with traditional cardiovascular risk factors: The African-PREDICT study. Nutrition, Metabolism and Cardiovascular Diseases. 2020 Jun; 30(6): 925-931. PMid:32278609
  14. Sökmen E, Uçar C, Sivri S, Çelik M, Güçlü K. Relationship of growth differentiation factor-15 with aortic stiffness in essential hypertension. Future Science OA. 2019 Aug; 5(7): FSO406. PMid:31428452 PMCid:PMC6695523
  15. Andersson C, Enserro D, Sullivan L, Wang TJ, Januzzi JL, Benjamin EJ, et al. Relations of circulating GDF-15, soluble ST2, and troponin-I concentrations with vascular function in the community: The Framingham Heart Study. Atherosclerosis. 2016 May; 248: 245-251. PMid:26972631 PMCid:PMC5018232
  16. Sökmen E, Uçar C, Sivri S, Çelik M, Boduroğlu Y, Erer M, et al. Association between Growth Differentiation Factor 15 and Non-Dipping Circadian Pattern in Patients with Newly Diagnosed Essential Hypertension. Medical Principles and Practice. 2019; 28(6): 566-572. PMid:31117085 PMCid:PMC6944892
  17. Silva IVG, de Figueiredo RC, Rios DRA. Effect of Different Classes of Antihypertensive Drugs on Endothelial Function and Inflammation. International Journal of Molecular Sciences. 2019 Jul 14; 20(14): 3458. PMid:31337127 PMCid:PMC6678872
  18. Ridker PM, Danielson E, Rifai N, Glynn RJ. Valsartan, blood pressure reduction, and C-reactive protein: Primary report of the Val-MARC trial. Hypertension. 2006 Jul; 48(1): 73-79. PMid:16714425
  19. Tiryaki O, Usalan C, Buyukhatipoglu H, Sayiner ZA, Kilisli H. Effects of Lisinopril, Irbesartan, and Amlodipine on the Thrombogenic Variables in the Early and Late Stages of the Treatment in Hypertensive Patients. Clinical and Experimental Hypertension. 2012 Apr 3; 34(2): 145-152. PMid:21967026
  20. Kim K, Kim J, Baek M, Bae J. Novel factor Xa inhibitor, maslinic acid, with antiplatelet aggregation activity. Journal of Cellular Physiology. 2020 Apr 30. PMid:32356316